Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016

  • ID: 3802743
  • Drug Pipelines
  • 56 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ambrx, Inc.
  • Jyant Technologies, Inc.
  • Neurotez, Inc.
  • XL-protein GmbH
  • MORE
Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016

Summary

‘Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016’, provides in depth analysis on Leptin Receptor (OB Receptor or CD295 or LEPR) targeted pipeline therapeutics.

The report provides comprehensive information on the Leptin Receptor (OB Receptor or CD295 or LEPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (OB Receptor or CD295 or LEPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leptin Receptor (OB Receptor or CD295 or LEPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ambrx, Inc.
  • Jyant Technologies, Inc.
  • Neurotez, Inc.
  • XL-protein GmbH
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Leptin Receptor (OB Receptor or CD295 or LEPR) Overview

Therapeutics Development

Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Stage of Development

Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Therapy Area

Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Indication

Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Companies

Leptin Receptor (OB Receptor or CD295 or LEPR) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leptin Receptor (OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development

Aegerion Pharmaceuticals, Inc.

Ambrx, Inc.

Jyant Technologies, Inc.

Neurotez, Inc.

XL-protein GmbH

Leptin Receptor (OB Receptor or CD295 or LEPR) - Drug Profiles

ARX-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-0801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-0802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

memtin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metreleptin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize Leptin Receptor for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Leptin Receptor for Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leptin Receptor (OB Receptor or CD295 or LEPR) - Dormant Projects

Leptin Receptor (OB Receptor or CD295 or LEPR) - Discontinued Products

Leptin Receptor (OB Receptor or CD295 or LEPR) - Featured News & Press Releases

Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease

Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin

Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin

May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy

Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy

Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer’s Disease

Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy

Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy

Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy

Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy

Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy

Nov 16, 2010: Juvenile Diabetes Research Foundation And Amylin Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 56List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Aegerion Pharmaceuticals, Inc., H1 2016

Pipeline by Ambrx, Inc., H1 2016

Pipeline by Jyant Technologies, Inc., H1 2016

Pipeline by Neurotez, Inc., H1 2016

Pipeline by XL-protein GmbH, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 44List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Ambrx, Inc.
  • Jyant Technologies, Inc.
  • Neurotez, Inc.
  • XL-protein GmbH
  • MORE
According to the author's, recently published report 'Leptin Receptor - Pipeline Review, H1 2016'; Leptin Receptor (OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Furthermore, the author says; Leptin Receptor (OB Receptor or CD295 or LEPR) Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor - Pipeline Review, H1 2016' outlays comprehensive information on the Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 8 and 2 respectively.
Note: Product cover images may vary from those shown
5 of 5
Aegerion Pharmaceuticals, Inc.
Ambrx, Inc.
Jyant Technologies, Inc.
Neurotez, Inc.
XL-protein GmbH
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll